Enzalutamide

Enzalutamide
Product Description

Enzalutamide is used for the treatment of Prostate Cancer. Enzalutamide FC tablets come in three strengths, 40 mg, 80 mg and 160 mg, where the recommended dose is 160 mg as a single daily dose.
Coripharma`s generic version of Enzalutamide is being developed in our R&D facility located in Iceland, which is run solely on sustainable energy. We plan to have the dossier available in Q4 2026. Our business development team remains available to discuss opportunities with our customers.

Read more Show less

Coripharma

  • Country/Region:
    Iceland
  • On CPHI since:
    2020
  • Employees:
    100 - 249
Company types
Pharmaceutical company
View company profile
Categories
more categories Show less
Specifications
  • Selling Points
    Quality Service; Sustainability
More specifications Fewer specifications
Sales Markets
Show more Show less

Coripharma

  • Country/Region:
    Iceland
  • On CPHI since:
    2020
  • Employees:
    100 - 249
Company types
Pharmaceutical company
View company profile

More Products from Coripharma (4)

  • Ivacaftor

    Product Ivacaftor

    Ivacaftor is used for the treatment of Cystic Fibrosis (CF) which is an inherited life-threatening disease. Ivacaftor FC tablets come in two strengths, 75 mg and 150 mg, that can either be used as a monotherapy, or in combination with either tezacaftor or both tezacaftor and elexacaftor. Pivotal BE studies...
  • Coripharma Dossier List

    Product Coripharma Dossier List

    We offer out-licensing of our own developed dossiers, along with a range of services that enable our customers to take products to their respective markets at the date of patent expiry and under their own brand. Currently we have over 30 own developed dossiers either in our pipeline or already available. C...
  • Ponatinib

    Product Ponatinib

    Ponatinib FC tablets come in three strengths, 15 mg, 30 mg and 45 mg and are used to treat Leukemia. Pivotal BE study is completed and passing and the dossier will be available in Q1 2026. DCP slot requested in May 2026. 

    Coripharma`s generic version of Ponatinib is being developed in our R&...
  • Binimetinib

    Product Binimetinib

    Binimetinib FC tablets come in two strengths, 15 mg and 45 mg, and are used in combination with Encorafenib for the treatment of Melanoma. Pivotal BE studies for Binimetinib are planned in Q4 2025 and the dossier will be available in Q2 2026. DCP slot requested in September 2026.

    Coripharma`s g...